Ipsen pays Day One $111M up­front for ex-US rights to pe­di­atric brain tu­mor drug

In an­oth­er move to boost its on­col­o­gy port­fo­lio, Ipsen is hand­ing Day One Bio­phar­ma­ceu­ti­cals $111 mil­lion up­front so it can take the pe­di­atric brain tu­mor …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER